Skip to main content

Table 2 Changes in laboratory indices before and after treatment

From: Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

Laboratory index Group Before treatment 1 week after treatment 1 month after treatment F P
WBC
(×109/L)
R 2.55 ± 2.21 5.45 ± 3.32 5.74 ± 2.52 8.896 0.002
C 4.29 ± 3.37 8.77 ± 4.69 9.62 ± 5.17
Fibrinogen
(g/L)
R 0.9 ± 0.35 1.65 ± 0.66 2.17 ± 0.89 86.247 <  0.001
C 1.36 ± 0.49 2.62 ± 0.21 3.94 ± 1.45
Ferritin (μg/L) R 17,090 ± 17,586 828.1 ± 646.4 178.9 ± 166.1 22.493 <  0.001
C 12,579 ± 18,748 4765.6 ± 4562.2 597.6 ± 783.3
IL-2R(U/mL) R 9381.3 ± 12,865.4 2540 ± 1381.5 494.2 ± 195.8 5.146 0.036
C 1784.5 ± 516.4 760 ± 155.6 390 ± 84.8
  1. WBC white blood cell; IL-2R interleukin-2 receptor; Group R ruxolitinib-treated group; Group C control group treated with conventional therapy. P-values describe comparisons within each group before and after treatment